Temporary targeting of VEGF with low-dose bevacizumab resulted in an impressive decrease in the severity of epistaxis thereby achieving transfusion-independent intervals of 258 and 181 days on initiation and reinitiation of systemic low-dose bevacizumab therapy and the patient is currently RBC transfusion-independent. This evidence concerns the gene VEGFA and epistaxis.